<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(1)</volume><submitter>Palandri F</submitter><journal>Blood cancer journal</journal><pagination>4</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7791065</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.</pubmed_title><pmcid>PMC7791065</pmcid><pubmed_authors>Pugliese N</pubmed_authors><pubmed_authors>Cuneo A</pubmed_authors><pubmed_authors>Heidel F</pubmed_authors><pubmed_authors>Bonifacio M</pubmed_authors><pubmed_authors>Crugnola M</pubmed_authors><pubmed_authors>Cavo M</pubmed_authors><pubmed_authors>Trawinska MM</pubmed_authors><pubmed_authors>Benevolo G</pubmed_authors><pubmed_authors>Martino B</pubmed_authors><pubmed_authors>Isidori A</pubmed_authors><pubmed_authors>Iurlo A</pubmed_authors><pubmed_authors>Breccia M</pubmed_authors><pubmed_authors>Latagliata R</pubmed_authors><pubmed_authors>Scaffidi L</pubmed_authors><pubmed_authors>Palandri F</pubmed_authors><pubmed_authors>Ciantia F</pubmed_authors><pubmed_authors>Bosi C</pubmed_authors><pubmed_authors>Lemoli RM</pubmed_authors><pubmed_authors>Stella R</pubmed_authors><pubmed_authors>Binotto G</pubmed_authors><pubmed_authors>Tieghi A</pubmed_authors><pubmed_authors>Pane F</pubmed_authors><pubmed_authors>Abruzzese E</pubmed_authors><pubmed_authors>Bartoletti D</pubmed_authors><pubmed_authors>Polverelli N</pubmed_authors><pubmed_authors>Caocci G</pubmed_authors><pubmed_authors>Vianelli N</pubmed_authors><pubmed_authors>Palumbo GA</pubmed_authors><pubmed_authors>Semenzato G</pubmed_authors><pubmed_authors>Cavazzini F</pubmed_authors><pubmed_authors>Bergamaschi M</pubmed_authors><pubmed_authors>Tiribelli M</pubmed_authors><pubmed_authors>Cattaneo D</pubmed_authors><pubmed_authors>Krampera M</pubmed_authors><pubmed_authors>Elli EM</pubmed_authors><pubmed_authors>Auteri G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.</name><description/><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2025-04-25T20:39:45.776Z</modification><creation>2025-04-06T08:26:16.424Z</creation></dates><accession>S-EPMC7791065</accession><cross_references><pubmed>33414394</pubmed><doi>10.1038/s41408-020-00392-1</doi></cross_references></HashMap>